Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T16:08:41.615Z.
Calculation as of: 2026-10-06T16:08:41.615Z.
Quote observation: 2026-10-06T16:05:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 65e01e2061821370315a71c231e2ba412a336584d38d2dbcbde0d0d1c3e2cd16
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Mobia Medical, Inc. Common Stock
Market Cap
$307.89M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$300.93M
EV/Sales Ratio
N/A
TTM Avg
727.13x
3Y Avg
2593.81x
5Y Avg
3058.46x
Market Cap
$320.67M
EV/Sales Ratio
8.53x
TTM Avg
9.26x
3Y Avg
9.89x
5Y Avg
12.44x
Market Cap
$294.51M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$321.43M
EV/Sales Ratio
4.77x
TTM Avg
2.58x
3Y Avg
4.18x
5Y Avg
5.19x
Market Cap
$322.77M
EV/Sales Ratio
22.63x
TTM Avg
22.11x
3Y Avg
20.81x
5Y Avg
20.81x
Market Cap
$289.99M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$288.14M
EV/Sales Ratio
9.87x
TTM Avg
250.43x
3Y Avg
190.32x
5Y Avg
110.72x
Market Cap
$287.22M
EV/Sales Ratio
0.54x
TTM Avg
2.42x
3Y Avg
2.68x
5Y Avg
2.39x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mobia Medical, Inc. Common Stock (MOBI) | $307.89M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $300.93M | N/A | 727.13x | 2593.81x | 3058.46x |
| C4 Therapeutics, Inc. (CCCC)vs › | $320.67M | 8.53x | 9.26x | 9.89x | 12.44x |
| Larimar Therapeutics, Inc. (LRMR)vs › | $294.51M | N/A | N/A | N/A | N/A |
| Avita Medical Inc. (RCEL)vs › | $321.43M | 4.77x | 2.58x | 4.18x | 5.19x |
| CapsoVision, Inc. (CV)vs › | $322.77M | 22.63x | 22.11x | 20.81x | 20.81x |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $289.99M | N/A | N/A | N/A | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.14M | 9.87x | 250.43x | 190.32x | 110.72x |
| Standard BioTools Inc. (LAB)vs › | $287.22M | 0.54x | 2.42x | 2.68x | 2.39x |
| ClearPoint Neuro, Inc. (CLPT)vs › | $326.29M | 8.54x | 11.65x | 9.91x | 10.67x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
